A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial.

ABSTRACT:

Background

Low-grade serous and endometrioid ovarian cancers and adult-type granulosa cell tumors are rare ovarian malignancies that show high estrogen receptor positivity. Recurrences of these subtypes of ovarian cancer are often treated with conventional chemotherapy, although response rates are disappointing.

Primary objective

To determine the overall response rate of the combination therapy of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancers.

Study hypothesis

The combination therapy of abemaciclib and letrozole will provide a clinically meaningful therapeutic benefit, with an overall response rate of >25%.

Trial design

This is a phase II, international, multicenter, open-label, single-arm study to evaluate the effic

SUBMITTER: Ottenbourgs T 

PROVIDER: S-EPMC10982620 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature